Commentary · 27 May 2026
Conference abstractPublished 17 Sep 2018
Anthranilic acid derivatives as novel antiglycation and antidiabetic agents as possible leads against diabetes and associated complications
Dr Panjwani Center for Molecular Medicine and Drug Research, Pakistan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Diabetes mellitus is a chronic heterogeneous disorder. It is commonly presented with elevated levels of blood glucose and glucose intolerance, as a consequence of insulin deficiency and defective insulin action, or both. Currently, diabetes is affecting 415 million people globally. By 2040 this figure will rise to 642 million, as reported by the International Diabetes Federation. According to the WHO, diabetes is the third highest risk factor for premature death, after hypertension and cigarette smoking. In high-income countries, it is estimated that approx. 87-91% of all people living with diabetes have type 2 diabetes, 7-12% have type 1 diabetes and 1-3% have other types of diabetes. Currently available oral antidiabetic drugs include metformin and sulfonylureas. They play a pivotal role in the treatment of type 2 diabetic patients. Despite intensive attempts towards long-term management of type 2 diabetes, maintaining near euglycemic condition in these patients remains a major challenge. Recently, the molecules based on anthranilic acid scaffold have gained much attention in drug discovery and development. Anthranilic acid and its derivatives are constituents of many bioactive molecules. Both experimental and preclinical studies have explained the medicinal properties of anthranilic acid derivatives, including matrix metalloproteinase inhibition, anticancer, anti-inflammatory, antiglycation and analgesic activities. Our research group currently established that anthranilic acid derivative posses anti-diabetic effects, improved blood glucose levels and enhance insulinotropic action in diabetes animal model. This novel entity protects islet beta-cells, at least partly, via decreasing the intracellular reactive oxygen species (ROS) production.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Humera Jahan”
- BylineArticles whose byline prints “M Iqbal Choudhary”
